Stem Cell Clinic

Sen. Tom Cotton: Contraband cell phones in prisons are a threat Congress should act on – Fox News

By adminOctober 6, 2019Uncategorized

Earlier this year, we learned that Martin Shkreli, a conman and convicted felon, was secretly running an investment company from prison using a contraband cell phone.

Shkreli, also known as the Pharma Bro, achieved infamy in 2015 for jacking up the price of a medicine needed by a small group of very sick patients to enrich himself and his investors. He was convicted of fraud in 2017 and sent to prison.

Prison is supposed to keep criminals out of our communities, but as Shkrelis example shows, contraband cell phones allow inmates to continue their crime sprees from behind bars. Jamming cell phone signals from prison is the most effective way to counteract this dangerous trend. But first, the federal government has to let us do it.

FLORIDA MOM, DAUGHTER SENT CONTRABAND TO PRISON VIA DRONE DELIVERY, DEPUTIES SAY

Contraband cell phones have quickly become inmates most dangerous connection to the outside world. As mobile phones have become cheaper and easier to conceal, theyve proliferated in prisons across the country, including in my home state, Arkansas.

A little over a decade ago, convicted drug dealer Charles Wilson drove off prison grounds near Lincoln County on a tractor, where he was whisked away by several accomplices waiting at a prearranged location. Wilson was only recaptured after a 10-day manhunt that wasted precious police resources and endangered law-abiding citizens in nearby towns. The Wilson gang plotted his escape using a cell phone smuggled to him by his daughter.

CLICK HERE TO SIGN UP FOR OUR OPINION NEWSLETTER

Contraband cell phones were relatively rare when Wilson escaped in 2008, but theyve since become a favorite tool of incarcerated criminals. Its impossible to know how many cell phones are circulating within prison walls, but the number is easily in the thousands in my state alone. Arkansas correctional officers discovered 36 contraband cell phones in 2012; six years later, they discovered 1,637.

Prisoners use this contraband to circumvent official, monitored forms of communication and plot criminal activity. Contraband cell phones have been used to scam, blackmail, and even plot attacks on people outside prison walls. Captain Robert Johnson, a former officer at Lee Correctional Institution in South Carolina, was shot six times in his home by a gunman acting on orders from a prison inmate using a contraband cell phone. Johnson now campaigns full time to stop contraband cell phones in prison.

Prison authorities have responded to the flood of contraband with new technology and methods, including cell phone-detecting devices and enhanced screenings. These tools have uncovered thousands of contraband cell phones, but thousands more have slipped through the cracks. Tougher measures are needed to secure our prisons and keep law-abiding people safe.

Installing jammers in prisons would turn inmates cell phones into paperweights, disrupting their criminal networks and drying up a major source of contraband.

The most effective, proven method to stop contraband cell phones is to jam all phone signals within prison walls. Unfortunately, flawed federal regulations prevent state prison officials from jamming phone signals.

Some people fear that cell phone jammers could disrupt phone service for law-abiding people close to prisons. However, modern jamming technology can be narrowly targeted to minimize disruption to people outside of prison walls. Cell phone jammers installed at a South Carolina prison as part of an experiment earlier this year rendered phones useless inside prisoners cells, but didnt affect phones several feet from the cell window. Another test at a federal prison in Maryland came to the same conclusion.

Its time to fix the federal regulations that prohibit jamming technology and give prisons the tools they need to fight contraband. The Cellphone Jamming Reform Act, a bill I introduced earlier this year, would accomplish this goal by allowing prisons to block cell phone signals within their housing facilities.

CLICK HERE FOR THE ALL-NEW FOXBUSINESS.COM

Installing jammers in prisons would turn inmates cell phones into paperweights, disrupting their criminal networks and drying up a major source of contraband. Most important, the Cellphone Jamming Reform Act would ensure inmates contact with the outside world takes place on our terms, not theirs, limiting criminals opportunities to take advantage of law-abiding citizens.

Contraband cell phones have become the most serious security risk prisons face today, but they dont have to be. We have the ability to make our communities safer right now, if the federal government will just get out of the way.

CLICK HERE TO READ MORE BYSEN. TOM COTTON

Originally posted here:
Sen. Tom Cotton: Contraband cell phones in prisons are a threat Congress should act on - Fox News

Scientists find timekeepers of gut’s immune system – Washington University School of Medicine in St. Louis

By adminOctober 6, 2019Uncategorized

Visit the News Hub

Targeting such cells may lead to treatments for digestive ailments

An immune cell that helps set the daily rhythms of the digestive system has been identified by researchers at Washington University School of Medicine in St. Louis. The findings open the door to new treatments for digestive ailments targeting such cells.

As people go through their daily and nightly routines, their digestive tracts follow a routine, too: digesting food and absorbing nutrients during waking hours, and replenishing worn-out cells during sleep. Shift work and jet lag can knock sleep schedules and digestive rhythms out of whack. Such disruptions have been linked to increased risk of intestinal infections, obesity, inflammatory bowel disease and colorectal cancer, among others.

Now, researchers at Washington University School of Medicine in St. Louis have identified a type of immune cell that helps keep time in the gut. Such cells, known as type 3 innate lymphoid cells (ILC3), are responsible for keeping the intestine operating in a normal, healthy manner. The researchers found that so-called clock genes are highly active in such cells and that the cells production of immune molecules track with the activity of the clock genes. When the researchers eliminated a key clock gene from mice, the animals failed to produce a subset of ILC3 cells and struggled to control a bacterial infection in the gut.

The findings, published Oct. 4 in Science Immunology, help explain why disruptions to circadian rhythms are linked to gastrointestinal problems. Further, they suggest that targeting clock genes could affect immune cells and help counter the negative effects of erratic sleep schedules associated with intestinal illnesses.

Its become increasingly clear that the disruptions of circadian rhythms so common in modern life shift work, jet lag, chronic sleep deprivation have harmful effects on peoples health, but we still dont know a lot about how exactly sleep disruptions cause these problems, said senior author Marco Colonna, MD, the Robert Rock Belliveau MD Professor of Pathology and a professor of medicine. What weve found here is that circadian rhythms directly affect the function of immune cells in the gut, which could help explain some of the health issues we see, such as inflammatory bowel disease and metabolic syndrome.

ILC3 cells maintain equilibrium in the gut by fortifying the barrier between the trillions of bacteria that normally live inside the gut and the cells that make up the intestine itself. They also produce immune molecules that help the guts immune system avoid overreacting to harmless microbes and food particles, while preserving its ability to combat disease-causing micro-organisms.

Colonna and colleagues have studied ILC3 cells for years, but it wasnt until first author Qianli Wang and second author Michelle Robinette, MD, PhD both graduate students in Colonnas lab at the time noticed that clock genes were highly activated in ILC3 cells that they began to wonder whether the cells could link circadian rhythms to the guts immune system.

If ILC3 cells are attuned to circadian rhythms, they can anticipate when nutrition is going to arrive in the intestine, which is also when dangerous bacteria might accidentally be consumed and arrive in the gut, too, Wang said. For optimal functioning, the gut needs to be prepared for these daily rhythms, and these cells play a pivotal role in that process.

By studying ILC3 cells taken from mouse intestines at six-hour intervals, the researchers found that the activity of clock genes varied in a predictable pattern over the course of a day, and that the activity of genes for immune molecules tracked with the clock genes. When they put some mice on a schedule similar to one experienced by a shift worker an eight-hour change in the light-dark cycle every two days the ILC3 cells no longer functioned normally. They produced low levels of immune molecules when stimulated to respond to an infection. Further, when mice were genetically modified to lack the clock protein REV-ERB alpha, the animals failed to develop normal quantities of ILC3 cells.

I think its fair to say that ILC3 is under circadian rhythm regulation and certain key circadian genes are crucial for ILC3 cells to develop and function, Wang said.

Wang and Colonna suspected that a paucity of ILC3 cells or a change in ILC3 behavior could affect the bodys ability to fight intestinal infections. Using mice that lack the clock protein as well as healthy mice for comparison the researchers studied the effect of infection with the bacterium Clostridium difficile, which can cause severe diarrhea in people. The mice without the clock protein failed to mount an effective defense: Their ILC3 cells produced more of a damaging immune molecule and less of a protective immune molecule, and the bacteria spread more widely in their bodies.

The equilibrium of the gut is upset by disruptions to circadian rhythms, Wang said. ILC3 cells are so important to gut equilibrium that we may be able to counter some of these disruptions by targeting clock genes in ILC3 cells.

The researchers are continuing to study the role of circadian rhythms on the digestive tract.

The emerging relevance of the circadian regulation in gut health is likely to impact medical and hospital practice, Colonna said. I think we will have to start taking circadian rhythms of the gut cells into consideration when choosing optimal timing for nutritional and pharmacological interventions.

Wang Q, Robinette ML, Billon C, Collins PL, Bando JK, Fachi JL, Scca C, Porter SI, Saini A, Gilfillan S, Solt LA, Musiek ES, Oltz EM, Burris TP, Colonna M. Circadian rhythmdependent and circadian rhythmindependent impacts of the molecular clock on type 3 innate lymphoid cells. Science Immunology. Oct. 4, 2019. DOI: 10.1126/sciimmunol.aay7501

This study was supported by the National Institutes of Health (NIH), grant numbers AI095542, DE025884, AI134236, AI134035, MH092769, K99 DK118110, and T32 GM007200; Pfizer; Crohns & Colitis Foundation; and anonymous donors.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Continued here:
Scientists find timekeepers of gut's immune system - Washington University School of Medicine in St. Louis

Novartis and Microsoft Team Up to Advance Medicine with AI – FinSMEs

By adminOctober 6, 2019Uncategorized

Novartis(SWX: NOVN), a multinational pharmaceutical company based in Basel, Switzerland, is launching an AI innovation lab to enable its associates to use AI across the business.

The company selected Microsoft Corp. as its strategic AI and data-science partner. The new lab aims to bolster Novartis AI capabilities from research through commercialization and accelerate the discovery and development of transformative medicines for patients worldwide.

As part of the strategic collaboration, Novartis and Microsoft have committed to a multi-year research and development effort. The lab will bring AI to Novartis associates. By bringing together vast amounts of Novartis datasets with Microsofts advanced AI solutions, it will create new AI models and applications that can augment associates capabilities to take on the next wave of challenges in medicine.The lab will use AI to tackle hard computational challenges within the life sciences, starting with generative chemistry, image segmentation & analysis for smart and personalized delivery of therapies, and optimization of cell and gene therapies at scale.

Microsoft and Novartis will also collaborate to develop and apply next-generation AI platforms and processes that support future programs across these two focus areas. The overall investment will include project funding, subject-matter experts, technology, and tools.

Joint research activities will include co-working environments on Novartis Campus (Switzerland), at Novartis Global Service Center in Dublin, and at Microsoft Research Lab (UK) starting with tackling personalized therapies for macular degeneration; cell & gene therapy; and drug designBasel, and Redmond.

Continued here:
Novartis and Microsoft Team Up to Advance Medicine with AI - FinSMEs

Evaluation Of Mean Platelet Volume, Red Cell Distributed Width And Neu | NDT – Dove Medical Press

By adminOctober 6, 2019Uncategorized

Hasan Bykaslan,1 Mehmet Asolu2

1Department of Emergency Medicine, Harran University Medical Faculty, Sanliurfa, Turkey; 2Psychiatry Department, Harran University Medical Faculty, Sanliurfa, Turkey

Correspondence: Hasan BykaslanDepartment of Emergency Medicine, Harran University Medical Faculty, Sanliurfa, TurkeyTel +90 530 644 6845Email hasanbuyukaslan@hotmail.com

Background: The pathophysiology of conversion disorder (CD) is still not fully established. Many psychiatric disorders are known to be associated with inflammatory processes. We aimed to compare the routine hemogram values of CD patients with those of the participants in the healthy control group, to assess the inflammation levels of the two groups.Methods: This study was conducted with CD patients (n=158) and healthy controls (n=145). Routine hematological parameters were examined in each participant. Group comparisons were made with MannWhitney U-test and Students t-test. Regression analysis and receiver operating curve (ROC) analysis were also performed for the analysis of independent predictors.Results: The comparisons revealed that while neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), platelet, neutrophil, red cell distribution width (RDW), and mean platelet volume (MPV) were significantly higher in CD group (P<0.05), lymphocyte was decreased in that group (P>0.05). Multivariate and ROC analyses showed MPV, RDW, and NLR as independent predictors (P<0.05). ROC curve showed that MPV values of 7.8 or above could predict the CD with 84% sensitivity and 85% specificity (area under curve [AUC]=0.878; 95% confidence interval [CI]: 0.8170.939), RDW values of 11.0 or above could predict the CD with 82% sensitivity and 73% specificity (AUC=0.871; 95% CI: 0.8150.926), and NLR values of 1.8 or above could predict the CD with 85% sensitivity and 78% specificity (AUC=0.865; 95% CI: 0.8020.929).Conclusion: CD is related to the acute inflammatory process. MPV, RDW, and NLR can reflect this inflammation. These parameters could be used in differential diagnosis; increased RDW and MPV levels can be used as a novel marker in CD.

Keywords: conversion disorder, inflammation, hematologic tests

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Original post:
Evaluation Of Mean Platelet Volume, Red Cell Distributed Width And Neu | NDT - Dove Medical Press

On creativity, plasticity and repentance – Arutz Sheva

By adminOctober 5, 2019Embryonic Stem Cells

The young Israeli patient I visited in the isolation room at the Dana Farber Cancer Institute in Boston in the late 1970s was very ill. Ravages of the disease and its harsh treatment were clearly evident.

Diagnosed with a uniformly terminal disease, he had traveled to this renowned center in the Longwood Medical Area to be treated with a newly developed regimen of aggressive therapy. This world-famous academic hub is the medical campus where Harvard Medical School and many of its affiliated hospitals are all located. Major breakthroughs in medicine were developed here, including the first curative treatment of leukemia, the first kidney transplant, the first use of an electrical current to restore heart rhythm. It was here that creative man leaped forward with innovative advances that saved lives.

At the time I was a post-doctoral research fellow at Harvard Medical School. Our family resided several houses from the Ravs daughters home where the Rav was living, and our Maimonides community was fortunate to be able to spend eight to ten hours with the Rav every weekend in prayer and in learning. The creative gesture so central to the Ravs philosophy of halakhic man is a prime characteristic of biomedical research, and my oscillation between the universe of cutting edge biomedical research and the world of Torah learning with the Rav, while worlds apart, was harmonious. With the Rav often expressing curiosity about aspects of my research, I began to intuit that the work might not be merely creative but in fact a religious gesture.

A central theme in the Ravs weltanschauung is his emphasis on halakhic mans creative gesture. Ish haHalakhahs mission and continuous challenge are to heal and repair a purposely flawed world, for in the creation process a modicum of chaos was formed prior to the worlds creation and deliberately injected into both organic and inorganic matter, including into man himself.[1]

Man himself symbolizes, on the one hand, the most perfect and complete type of existence, the image of God, and, on the other hand, the most terrible chaos and void to reign over creation.[2] In order to enable man to cope with his inexorable chaos and sin, the tool of repentance was also created prior to the worlds formation (Pesahim 54a).

In a reference to creative introspection in Eight Chapters, Maimonides states: The perfect man needs to inspect his moral habits, weigh his actions, and reflect upon the state of his soul every single day. Whenever he sees his soul inkling toward one of the extremes, he should rush to cure it and not let the evil state become established (chap. 4).

Max Scheler, an early proponent of positive creative repentance, points out that modern philosophy, on the other hand, sees in retrospection and repentance mostly a negative, superfluous, uneconomical act due to disharmony of the mind and ascribed to lack of thought, sickness or various illusions..[3]

Emulating Maimonides, the Rav emphasizes an essential continuous remodeling, a re-creation of the sinners self as being a healthy, critically indispensable creative process. Halakhic man is engaged in self-creation, in creating a new I. He does not regret an irretrievably lost past but a past still in existence, one that stretches into and interpenetrates with the present and the future.[4]

The Ravs perspective on repentance is related to Schelers definition of creative repentance and to Henri Bergsons distinction between subjective, qualitative time-perception versus chronos, quantitative objective time. Both Scheler and Bergson ascribe to the principle of memory and experiential plasticity. The concept of plasticity, the property of being easily molded and remolded, has received intense scientific attention in the last decade, especially as related to the field of memory and neuroscience.

The presumed inability of the brain to generate new cells or to establish new neural networks is currently vigorously challenged and has indeed been proven incorrect. The process by which man can modify imprinted memories to affect his present and future behavior pattern is currently under scientific investigation. Epigenetic biochemical modifications of DNA and changes in neural networks triggered by ongoing experiences have been documented to alter both content and intensity of memories. The association between past triggering stimuli and the resurfacing of memories and behavior patterns has been shown to be moldable utilizing imaging and histological techniques. Previous memories can be reinforced, intensified, modified, or completely erased.

We no longer look at our genetic makeup and the mature brain as a fixed template that predicts our phenotype, and no longer are our memories an unalterable code. Rather, increasingly, biochemical data support the idea that they are templates upon which environmental and emotional stimuli can impact. Biochemical changes in the brain triggered by environmental and behavioral patterns were identified in identical twins raised in different environments. Scientists have defined conditions in which terminally differentiated cells, such as mature skin cells, which we assumed could never return to their embryonic pluripotent stem-cell status, have in fact definitively reverted and reprogrammed to evolve into new cell types. Recent reports have described the astonishing generation of live mice from skin cells reengineered to be ova.

If cells can revert to their embryonic state, if gene expression can be reprogrammed, if the brain can generate new nerve cells and establish new neural networks, the view of repentant man as a biologically defined new self is viable.

David Anderson from the California Institute of Technology describes a fascinating neuro-anatomical observation. The center in the brain that orchestrates emotion is the amygdala. It communicates with the hypothalamus, which houses the cells that control instinctive behavior like parenting, feeding, mating, fear, and fighting. Anderson found that a nucleus of cells within the hypothalamus contain two distinct populations of neurons: one that regulates aggression and one that regulates mating. About 20 percent of the cells in this nucleus are active both during mating activity and during aggressive behavior, which suggests that these two circuits are linked. How does the brain regulate these mutually exclusive behavior patterns? Anderson found that depending on the specific stimuli applied to this area it can trigger either mating activity or aggression.

Perhaps creating a new self through repentance from love (On Repentance, pp. 163) is associated with using mechanisms previously utilized for aggression and fear for productive activity such as love and fertility. A similar idea is found in the Babylonian Talmud (Shabbat 156a): He who is born under Mars will be a shedder of blood. Rabbi Ashi said: Either a surgeon, a thief, a slaughterer, or a circumciser. Through biochemical processes induced by the intense experiences of the teshuvah process confession, sacrifice, remorse, shame and a commitment to a new I a new self can emerge.

* * *

A decade after I visited the seriously ill young man at the Dana Farber Cancer Institute, the facility where chaos reigns and where creative man is faced with overwhelming challenges, I attended a scientific conference in Tiberias, burial place of Maimonides. I learned that a daily minyan was available at a nearby archeological site of an ancient synagogue on the shores of the magnificent Sea of Galilee. I was welcomed by a group of yeshiva students from Bnei Brak who had been coming weekly to maintain a minyan at this historical site.

Following services I was approached by a bearded man, who inquired:Are you Dr. Goldberg?

Since I had never practiced medicine in Israel I was surprised to be addressed as a physician.

Do you remember me? he asked. I am that patient you visited at the Dana Farber so many years ago. I am healthy, married and have several children.

The Prophets and the Torah as well recognized a strong connection between sin and illness on the one hand and between repentance and healing on the other (On Repentance, p. 80).

Through the creative gesture both the body and the spirit can be remodeled and healed.

Notes:

1. See Rabbi Joseph B. Soloveitchik, Halakhic Man (Philadelphia, 1983), p. 102.

2. Halakhic Man, p. 109.

3. Max Scheler, On the Eternal in Man (New Brunswick, NJ, 2010), p. 36.

4. Halakhic Man, p. 113.

Read more from the original source:
On creativity, plasticity and repentance - Arutz Sheva

UW Medicine receives $50 million donation to start brain institute – Lewiston Morning Tribune

By adminOctober 5, 2019Stem Cell Medical Center

SEATTLE A pair of philanthropists from Bellevue have given $50 million to UW Medicine to create an institute focused on developing treatments for brain disorders such as addiction, depression and Alzheimers disease.

The money, donated by Lynn and Mike Garvey, will kickstart the development of the Garvey Institute for Brain Health Solutions.

This will be the second neuroscience-focused institute in Seattle. The Allen Institute for Brain Science examines how the brain works, while the new Garvey Institute will take a more clinical approach to brain health. The work done at each could mesh nicely together, said Dr. Jrgen Untzer, a professor and chairman of UWs psychiatry and behavioral sciences department, which will be home to the Garvey Institute.

Garvey Institute researchers will build on work already being done at UW Medicine, and will also partner with scientists from within the University of Washington and other local health systems, Untzer said.

The goal is not only to develop brain solutions but to get them quickly put into practice, he said.

In addition to clinical research on treatments for brain disorders, the money will also fund training efforts for scientists and researchers from different disciplines at the institute, as well as a place for them to work together.

In its first five years, the Garvey Institute will focus on three main areas: cognitive aging and brain wellness; the effects of physical and emotional trauma on the brain; and addiction.

At some point, almost every family is affected by a brain-health problem such as depression, Alzheimers disease or addiction, Lynn Garvey said in the news release. These diseases are so common and so devastating, and we wanted to do something to help.

The Garveys, who declined to be interviewed, have previously donated money to UW Medicines Institute of Stem Cell and Regenerative Medicine, the psychiatry and behavioral sciences department, Harborview Medical Center, and the heart regeneration and gastroenterology programs.

Mike Garvey is the primary founder of Saltchuk, a Seattle-based family of transportation and distribution companies.

See the original post:
UW Medicine receives $50 million donation to start brain institute - Lewiston Morning Tribune

UW Medicine receives $50 million donation to start institute to study addiction, Alzheimer’s and more – The Daily World

By adminOctober 5, 2019Stem Cell Medical Center

By Ryan Blethen

The Seattle Times

A pair of philanthropists from Bellevue have given $50 million to UW Medicine to create an institute focused on developing treatments for brain disorders such as addiction, depression and Alzheimers disease.

The money, donated by Lynn and Mike Garvey, will kickstart the development of the Garvey Institute for Brain Health Solutions.

This will be the second neuroscience-focused institute in Seattle. The Allen Institute for Brain Science examines how the brain works, while the new Garvey Institute will take a more clinical approach to brain health. The work done at each could mesh nicely together, said Dr. Jrgen Untzer, a professor and chair of UWs psychiatry and behavioral sciences department, which will be home to the Garvey Institute.

The goal is not only to develop brain solutions but to get them quickly put into practice, he said in an interview Wednesday.

These new programs will change the future of mental health and brain health in our region and beyond, Untzer said in a news release announcing the donation.

In its first five years, the Garvey Institute will focus on three main areas: cognitive aging and brain wellness, the effects of physical and emotional trauma on the brain, and addiction.

Mike Garvey is the primary founder of Saltchuk, a Seattle-based family of transportation and distribution companies that reports a consolidated annual revenue of nearly $2.75 billion.

American CryoStem Expands Investigator Team with Sub-Investigators for Post Concussive Syndrome IND – Yahoo Finance

By adminOctober 5, 2019Stem Cell Medical Center

The Company and the Principal Investigator announce the addition of sub-investigators to the clinical trial team with extensive experience assessing and treating athletes and military personnel suffering from concussion injury, traumatic brain injury and Post Concussion Syndrome

EATONTOWN, NJ / ACCESSWIRE / October 3, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced the selection of three new Investigators to assist the Principal Investigator with CRYO's Phase I clinical study of ATcell ("Investigational Drug") as part of a single center study under a protocol entitled: ATcell Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed via Intravenous Infusion for the Treatment of Post Concussion Syndrome (PCS) in Retired Military and Athletes.

Dr. Tal David, a Sport Medicine specialist and former NFL Head Team Physician for the San Diego Chargers, is going to be the Co-Principal investigator for the study. Sub-Investigators, Dr. Jason Bailie, PhD, Senior Clinical Research Director at the Defense and Brain Injury Center (DVBIC) at the Naval Hospital Camp Pendleton, CA and Dr. Ettenhofer, Director of Research Operations, Defense and Veterans Brain Injury Center (DVBIC) Naval medical Center, San Diego, CA were the key designers of the evaluation aspect of the study. This included advising on the pre-treatment evaluations to rule out complex psychological co-pathology as well as the outcome measures to follow the efficacy of the treatments, since the chronic injuries seen in athletes mirrors those issues found in the military with multiple concussions and blast injuries.

Under the direction of Dr. Hanson and Dr. David, the sub-investigators will be responsible for assessing and screening all applicants for participation and completing the ongoing assessment of each participant. These evaluations include patient physical and neuropsychological assessment, testing and screening, preparation of source documentation and collection of assessment results, and assistance with completion of the final study reports and publications. The surgical tissue collection, ATcell treatments and follow up clinical visits will be conducted at BioSolutions Clinical Research Center facility in Le Masa, CA. The Company is pleased to present a world class team with significant experience in chronic concussion syndromes.

PRINCIPAL INVESTIGATOR: Dr. Peter Hanson, MD, as previously announced on September 11, 2019, has been appointed as the Principal Investigator, for the Company's study. Dr. Hanson is also Medical Director of BioSolutions Clinical Research Center the clinical research facility engaged by the Company to conduct the Study. During Dr. Hanson's career he has participated in approximately 41 clinical studies of which he led 24 as principal investigator. His clinical studies have been sponsored by many of the biggest names in the pharmaceutical and biotech industry such as Pfizer, Sanofi, Bristol Meyers Squibb, Regeneron, Cytori and InGeneron.

CO-PRINCIPAL INVESTIGATOR: Dr. Tal David, M.D. is a board-certified orthopedic surgeon specializing in arthroscopic and sports medicine surgery, is certified in both Orthopedic Surgery and Orthopedic Sports Medicine. He practices in San Diego, CA as part of the Synergy Specialists Medical Group and the San Diego Stem Cell Treatment Center. He is a clinical faculty member of Orthopedic Surgery at UC San Diego and a faculty member of the San Diego Arthroscopy and Sports Medicine Fellowship. He has cared for injured athletes for 15 years and has served on the medical staff of various professional sports teams including more than 11 years as an NFL team physician. In addition to his private practice, he served as the former Head Team Physician for the San Diego Chargers NFL football team and is Medical Director for the San Diego Gulls, AHL hockey team.

SUB-INVESTIGATOR: Jason M. Bailie, Ph.D, is a neuropsychologist who serves as Senior Clinical Research Director of the Defense and Veterans Brain Injury Center (DVBIC), Naval Hospital in Camp Pendleton, CA. Dr. Baille currently directs research, clinical and educational activities and supervises research staff. He is responsible for clinical research program development, experimental design, human-subject recruitment, experimental procedural implementation, data acquisition, and statistical analysis for local and multi-site research studies. Additional duties include oversight of research compliance with Institutional Review Board for the Department of Navy, Department of Defense clinical research and human subject research policies; and facilitating grant acquisitions and management. He supervises a clinical staff of social workers and psychologists, educational outreach personnel and provides educational presentations and grand rounds to providers and service members in collaboration with DVBIC Regional Education Coordinator.

Story continues

SUB-INVESTIGATOR Mark L. Ettenhofer, Ph.D is a neuropsychologist and Director of Research Operations American Hospital Services Group (AHSG), Defense and Veterans Brain Injury Center (DVBIC), Naval Medical Center, San Diego (NMCSD): San Diego, CA.Dr. Ettenhofer's primary research focuses on the development and evaluation of novel approaches for neurocognitive assessment and rehabilitation of traumatic brain injury (TBI) for the US Navy. Dr. Ettenhofer currently directs DVBIC supported traumatic brain injury (TBI) research at NMCSD, including 8 approved protocols evaluating novel technologies for TBI assessment, methods for remediation of TBI-related impairment, natural history of TBI, and guidelines for progressive return to activity after injury. Additionally he provides programmatic review for DVBIC national research portfolio, supervises and mentors eight full-time staff members in research activities and is well published.

Overall, it is estimated that the cost of traumatic brain injuries (TBI) in the United States weighs in at $48.3 billion annually of which $31.7 billion is spent on hospitalization costs; an additional $16.6 billion is associated with costs attributed to fatalities. According to the Center for Disease Control, acute care and rehabilitation of brain injury patients in the United States costs about $9 billion to $10 billion per year. This does not include indirect costs to society and family caretakers due to lost productivity, work time and earnings, as well as costs linked to providing social services.

Brain Injury Cost

The Company stated that "The successful assembly of this expert team of investigators who are currently treating athletes and military personnel suffering from Concussive and Traumatic Brain Injury is a major step towards properly implementing, monitoring and effectively evaluating the treatment of the participants with ATcell. Working with this expert team will expand the Company's knowledge for treating concussion injury, traumatic brain injury and Post Concussion Syndrome and accelerate its ability to complete this Phase 1 study and provide the necessary input to continue our work toward final FDA approval of ATcell for Post Concussion Syndrome.

For further detailed Corporate or Regenerative Medicine information please visit:

http://www.americancryostem.com, request by email at info@americancryostem.com or gathering phone 732-747-1007

This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.

SOURCE: American CryoStem Corporation

View source version on accesswire.com: https://www.accesswire.com/561800/American-CryoStem-Expands-Investigator-Team-with-Sub-Investigators-for-Post-Concussive-Syndrome-IND

See the original post here:
American CryoStem Expands Investigator Team with Sub-Investigators for Post Concussive Syndrome IND - Yahoo Finance

Global Induced Pluripotent Stem Cells Market 2019 Innovative Trends and Insights Research upto 2024 – News Adopt

By adminOctober 5, 2019Induced Pluripotent Stem Cells

Global Induced Pluripotent Stem Cells Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023 presents the analytical view of the industry that will enable readers to formulate and develop critical strategies for their businesses future expansion. With this report on Induced Pluripotent Stem Cells market, we are discussing a deep elaboration of several cogent factors that will play a key role in global market development over the coming years. The report studies market growth, trends, consumption figures, and industry structure, product specification, advertising level, and market income, and predicts future growth for the forecast period from 2018 to 2023.

The overall data presented in the market research report has been extracted from reliable and authentic primary and secondary sources to deliver precise and valid information to our esteemed clients. The whole knowledge is based on latest industry news, opportunities, and trends.

DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report/global-induced-pluripotent-stem-cells-market-2018-by-333303.html#sample

Top Companies in Induced Pluripotent Stem Cells Market are as follows: Fujifilm Holding Corporation, Astellas Pharma Inc, Fate Therapeutics, Inc, Bristol-Myers Squibb Company, ViaCyte, Inc, Celgene Corporation, Aastrom Biosciences, Inc, Acelity Holdings, Inc, StemCells, Inc, Japan Tissue Engineering Co., Ltd, Organogenesis Inc,

This report provides an evaluation, individual revenue, market share, and growth rate of this market in these Top Regions covering: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Segment Types are as follows: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Others

Main applications of this Market are: Academic Research, Drug Development And Discovery, Toxicity Screening, Regenerative Medicine, ,

What is from the offering:

The report offers actionable insights to boost source-to-contract cycle performance in the market. It gives facts about the work to help stakeholders capture earnings as well as expand their company enterprise. This overall data will also help sourcing professionals enhance savings, formulate better strategies, develop sourcing best practices, know supplier and market challenges. The report will provide correct direction to enthusiastic businesses.

Advantages of Global Induced Pluripotent Stem Cells Market Report:

ACCESS FULL REPORT: https://www.fiormarkets.com/report/global-induced-pluripotent-stem-cells-market-2018-by-333303.html

Moreover, the report studies the Induced Pluripotent Stem Cells industry along with the import and export statistics, industry chain in the market as well as dynamics of demand and supply, product/service specifications, manufacturing capacities, productive manufacturing methods. The present scenario and the expansion likelihood of the market for 2018-2023 are covered in this report.

The report also evaluates the growth established by the market during the forecast period and research conclusions are offered. In addition, the report features innovation offerings, product diagrams, corporate plans, enterprise profile, and financial execution.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

Arash is the chief editor of News Adopt. He handles the responsibility of covering Technology news. Arash has a rich experience of 15 years in covering technology news. He is also an Adjunct Professor at the University of Southern California.

Here is the original post:
Global Induced Pluripotent Stem Cells Market 2019 Innovative Trends and Insights Research upto 2024 - News Adopt

New Rett Therapies May Stem From X-chromosome Reactivation Findings – Rett Syndrome News

By adminOctober 5, 2019Induced Pluripotent Stem Cells

Genes that are normally silenced in the X-chromosome transition from an off to an on state at different speeds, an event that is dependent on the action of certain proteins and enzymes, according to a recent study.

These findings may one day help design a targeted therapeutic strategy for Rett syndrome and other X-chromosome-linked genetic disorders.

The study, Dynamic reversal of random X-Chromosome inactivation during iPSC reprogramming, was published in the journal Genome Research.

Rett syndrome is a rare genetic disorder that affects girls almost exclusively and is characterized by developmental and intellectual disabilities.The condition is caused by mutations in theMECP2 gene, located on the X chromosome, that provides instructions to make a protein called MeCP2. This protein is responsible for maintaining synapses, which are the junctions between nerve cells that allow them to communicate.

Women carry two X chromosomes one from the mother and one from the father while men carry only one, inherited from the mother. To ensure that all genes in the X chromosome are expressed equally in men and women, a process known as X-chromosome inactivation takes place during embryonic development, at which time one of the two X chromosomes carried by females is randomly selected to be inactivated.

A potential way to treat Rett syndrome and other X-chromosome-linked disorders is to devise a strategy to reactivate the healthy copy of the gene on the inactive X-chromosome. This reactivation would occur at the early stages of embryonic growth.

In the study, researchers at KU LeuvenUniversity of Leuven and colleagues used a type of stem cell called induced pluripotent stem cells (iPSCs). These cells are usually derived from adult skin cells (fibroblasts) and behave similarly to embryonic cells, meaning they can give rise to nearly any type of cell in the body.

The team used adult fibroblasts from female mice and reprogrammed them back into iPSCs. Of note, both X chromosomes are active in IPSCs, making these cells a valuable tool to study the mechanisms behind chromosome reactivation.

Working with iPS cells has numerous advantages. Most importantly, when you reprogram female adult cells into iPS cells, both X chromosomes become active again. In other words: X-chromosome reactivation starts happening right under your microscope, Vincent Pasque, assistant professor at KU LeuvenUniversity of Leuven and the studys lead author, said in a news release.

We monitored almost 200 different X-linked genes throughout the X-chromosome reactivation process. What we found is that reactivation happens gradually: different genes require different amounts of time to become active again, said Irene Talon, one of the studys authors.

The researchers found that some genes reactivated early (as early as day 8 after reprogramming), while others took longer. Intermediate genes were reactivated between day 8 and 10, and others between day 10 and 13 (called late genes), while some took longer than 13 days (which were called very late genes).

The reason for the different pace in reactivation, the researchers found, was that the early genes were located closer to genes that escape X-chromosome silencing.

Additionally, these early genes were richer in sites for the binding of transcription factors required for the transition of cells into iPSCs. Of note, transcription factors are proteins that help turn specific genes on or off by binding to nearby DNA.

Specifically, the researchers found that the reactivation timing was dependent on histone deacetylases, which are enzymes that label DNA to be silenced and work like barriers to gene activation.

Our findings suggest that the explanation for this speed difference is a combination of the location of the gene in 3D space on the X chromosome and the role of proteins (transcription factors), and enzymes (histone deacetylases), in particular, Talon added.

X-chromosome reactivation was accompanied by a decrease in the levels of an RNA molecule, called Xist, which is known to be involved in the silencing of the X-chromosome.

Overall, these findings suggest that reactivation of X-linked genes requires the combined action of different players information that is key for the development of possible future therapies for Rett syndrome.

Its important to remember that were talking about very fundamental research here. Contributing to the development of a cure for Rett syndrome and similar disorders is our long-term goal, but it will take us a while to get there, and there are many hurdles to overcome, Pasque said.

We still need to figure out how to use the mechanism for a single gene, how to do it safely in patients, and how to target the right cells in the brain. We do not yet know how to overcome these formidable challenges but we do know that gaining a fundamental understanding of how things work is the crucial first step, he added.

Thats how science works: its a slow process.

Visit link:
New Rett Therapies May Stem From X-chromosome Reactivation Findings - Rett Syndrome News